Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H20ClF2N3O3S |
| Molecular Weight | 455.906 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CCCN1CCN(C2)C(=O)C3=CC(=C(F)C=C3Cl)S(=O)(=O)NC4=CC=CC=C4F
InChI
InChIKey=AGPIHNZOZNKRGT-CYBMUJFWSA-N
InChI=1S/C20H20ClF2N3O3S/c21-15-11-17(23)19(30(28,29)24-18-6-2-1-5-16(18)22)10-14(15)20(27)26-9-8-25-7-3-4-13(25)12-26/h1-2,5-6,10-11,13,24H,3-4,7-9,12H2/t13-/m1/s1
ABT-639 is a T-type calcium (Cav3.2) channel antagonist that was in development with AbbVie for the treatment for pain. ABT-639 is a potent and selective T-type calcium channel blocker. ABT-639 effectively reduces nociceptive and neuropathic pain in rats. ABT-639 produces robust antinociceptive activity in experimental pain models at doses that do not significantly alter psychomotor or hemodynamic function in the rat. ABT-639 blocks recombinant human T-type (Cav3.2) Ca2+ channels in a voltage-dependent fashion (IC50=2 uM) and attenuates low voltage-activated (LVA) currents in rat DRG neurons (IC50=8 uM). ABT-639 was significantly less active at other Ca²⁺ channels (e.g. Ca(v)1.2 and Ca(v)2.2) (IC₅₀ > 30 uM). ABT-639 has high oral bioavailability (%F = 73), low protein binding (88.9%) and a low brain:plasma ratio (0.05:1) in rodents.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A peripherally acting, selective T-type calcium channel blocker, ABT-639, effectively reduces nociceptive and neuropathic pain in rats. | 2014 Jun 15 |
|
| Optimization of ADME Properties for Sulfonamides Leading to the Discovery of a T-Type Calcium Channel Blocker, ABT-639. | 2015 Jun 11 |
|
| A Randomized, Double-Blind, Placebo-Controlled, Crossover Study of the T-Type Calcium Channel Blocker ABT-639 in an Intradermal Capsaicin Experimental Pain Model in Healthy Adults. | 2016 Mar |
Patents
Sample Use Guides
Healthy adult males (aged 21 to 55 years) were randomly assigned to receive single oral doses of ABT-639, pregabalin, and placebo. A single 100-mg dose of ABT-639 had no effect on experimental pain induced by intradermal capsaicin injection.
Route of Administration:
Oral
ABT-639 blocks recombinant human T-type (Cav3.2) Ca2+ channels in a voltage-dependent fashion (IC50=2 uM) and attenuates low voltage-activated (LVA) currents in rat DRG neurons (IC50=8 uM). ABT-639 is significantly less active at other Ca2+ channels (e.g. Cav1.2 and Cav2.2) (IC50>30 uM).
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
0G7D0CQ88I
Created by
admin on Sat Dec 16 08:09:12 GMT 2023 , Edited by admin on Sat Dec 16 08:09:12 GMT 2023
|
PRIMARY | |||
|
1235560-28-7
Created by
admin on Sat Dec 16 08:09:12 GMT 2023 , Edited by admin on Sat Dec 16 08:09:12 GMT 2023
|
PRIMARY | |||
|
300000041421
Created by
admin on Sat Dec 16 08:09:12 GMT 2023 , Edited by admin on Sat Dec 16 08:09:12 GMT 2023
|
PRIMARY | |||
|
DB15055
Created by
admin on Sat Dec 16 08:09:12 GMT 2023 , Edited by admin on Sat Dec 16 08:09:12 GMT 2023
|
PRIMARY | |||
|
46851313
Created by
admin on Sat Dec 16 08:09:12 GMT 2023 , Edited by admin on Sat Dec 16 08:09:12 GMT 2023
|
PRIMARY | |||
|
C118315
Created by
admin on Sat Dec 16 08:09:12 GMT 2023 , Edited by admin on Sat Dec 16 08:09:12 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
